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Introduction
Snakebites remain a source of considerable morbidity and mortality in 
many countries with an estimated global true incidence of envenomation 
exceeding five million a year, with about 100 000 of these cases 
developing severe sequelae.1 Despite the availability of polyvalent snake 
antivenom, inappropriate first aid, the regional effects of envenomation 
and inappropriate use of antivenom result in significant and at times 
potentially avoidable morbidity and mortality, particularly in children.2 
Snake venoms, the most complex of all poisons, are a mixture of 
over 20 enzymes and non-enzymatic compounds (neurotoxins 
and haemorrhagens) as well as other non-toxic proteins including 
carbohydrates and metals. Different species have differing proportions 
of most if not all of the mixtures.3,4,5 Immediate application of a broad, 
firm pressure immobilisation bandage over the bitten area, if possible 
over the entire limb, aimed at impeding lymphatic and capillary flow, 
together with limb immobilisation is effective in the field management of 
human snake envenomation.5,6 
Antivenom administration is indicated only if serious manifestations of 
envenomation are evident. Conventionally, 50 ml (five vials) to 150 ml 
(15 vials) is infused, depending on the severity of envenomation.3,7,8 
However, in patients who received half the conventional dose, there 
was no significant difference in the time taken for clotting to normalise.9 
Theoretically, there does not seem to be an upper dose limit and even 
45 vials have been used successfully in a patient.10 Antivenom is 
administered intravenously after a test dose.5 Intramuscular adminis-
tration of antivenom followed by standard hospital management led to a 
definite reduction in the number of patients with systemic envenomation, 
complications and mortality from Russell’s viper envenomation.11 
Although the best results from antivenom are observed within four hours 
of the bite,5 antivenom has been noted to be effective in symptomatic 
patients even when administered more than 48 hours after the bite. 
Reports suggest that antivenom was efficacious even 6 – 7 days 
after the bite in settings where patients presented late.12,13 Response 
to infusion of antivenom is often dramatic and normalisation of blood 
Abstract 
Background: Snakebites remain a source of considerable morbidity and mortality in many countries, with an estimated global true incidence of 
envenomation exceeding five million a year, with about 100 000 of these cases developing severe sequelae. Despite the availability of polyvalent 
snake antivenom, inappropriate first aid, regional effects of envenomation and inappropriate use of antivenom result in significant and at times 
potentially avoidable morbidity and mortality, particularly in children. The study was undertaken in Lephalale (previously Ellisras) Hospital, Limpopo 
Province, due to the frequency of snakebites managed at the hospital. 
Methods: This was a record-based retrospective study in which patient files with the diagnosis of snakebite were reviewed. The objective of this 
study was to document the management of snakebites at Lephalale Hospital, a rural hospital in South Africa. The hospital files of all patients managed 
at the hospital for snakebites from 1 January 1998 to 31 December 2001 were reviewed.
Results: Seventy patients were treated for snakebites during the study period. The results showed a male preponderance (60%) and a mean age 
of 27.3 years among the reported cases. Twenty-nine patients (41.1%) were bitten between dusk and dawn (18:00 and 06:00), 43 (61.4%) were 
bitten on the lower limb and the mean duration of admission in the wards was 4.2 days. Twenty-one bites (30%) were attributed to known poisonous 
snakes, 22 (31.4%) patients received polyvalent antivenom, 42 (60%) received promethazine, which has not been shown to prevent anaphylactic 
reactions, 12 (17.1%) developed complications and two died (a case fatality rate of 2.9%). None of the patients was given tetanus toxoid as 
prophylaxis, as no previous tetanus immunisation was documented.
Conclusions: The findings of this study highlight gaps in the management of snakebites at this rural hospital where they were treated frequently. It 
is crucial for primary care physicians to be familiar with the most common venomous snakes in South Africa and the management of their bites in 
humans. Elevation of the affected limb, administration of intravenous fluids and administration of analgesia, with close monitoring of patients during 
and after antivenom administration, form the basis of most clinical protocols on the management of snakebites.
  This article has been peer reviewed. SA Fam Pract 2009;51(3):224-227
Management of snakebites at a rural South African hospital
Ogunbanjo GA, MBBS, FCFP(SA), MFamMed, FACRRM, FACTM, FAFP(SA)
Department of Family Medicine and PHC, University of Limpopo (Medunsa campus), Pretoria, South Africa 
Correspondence to: Prof GA Ogunbanjo, e-mail: gao@intekom.co.za
Keywords: snake bite; rural; South Africa
Original Research: Management of snakebites at a rural South African hospital Original Research: Management of snakebites at a rural South African hospital
225 Vol 51 No 3SA Fam Pract 2009
pressure is an early response.14 Within 15 to 30 minutes, bleeding 
stops though coagulation disturbances may take up to six hours to 
normalise. Neurotoxicity improves from the first 30 minutes but 24 to 
48 hours may be required for full recovery.15 Hypersensitivity reactions 
may occur in 3–4% of cases, usually within 10 to 180 minutes after 
infusion is started. These usually respond to conventional management 
including adrenaline, antihistamine and corticosteroids.16 Of note is that 
intramuscular antivenom is ineffective in the South African context.
The National Health Laboratory Services (NHLS) produces a polyvalent 
antivenom that is effective against all venomous snakes common in 
Southern Africa except for the boomslang (Dispholidus typus) and the 
twig snake (Thelotornis capensis). The NHLS produces a monovalent 
antivenom specific for the boomslang; unfortunately, there is no 
antivenom for twig snake envenomation.7
Methods
This study was undertaken in Lephalale Hospital, which serves a 
predominantly rural population of roughly 90 000 people in Limpopo 
Province. A record-based, retrospective study design was used. All 
patients managed at the hospital for snakebites from 1 January 1998 to 
31 December 2001 were included in the study. To ensure that all relevant 
data were evaluated, the records of paramedics, nursing staff and 
doctors were reviewed. Epi-info 6.04 software was used for data capture 
and analysis. Both descriptive and multivariate analyses were done with 
chi-square tests used where appropriate for association of variables. This 
study was approved by the Research, Ethics and Publications Committee 
of the Medical University of Southern Africa (now the University of 
Limpopo, Medunsa Campus) and permission was obtained from the 
Department of Health and Welfare, Limpopo, to conduct the study.
Results
Data were obtained on 70 patients of which 42 (60%) were males and 
28 (40%) were females. The age range was between one and 70 years 
with a mean of 27.3 years (SD ± 15.7 years). Only 65 files (92.9%) 
had adequate information for accurate determination of duration of 
admission. The period of admission ranged from zero to 26 days with a 
mean of 4.2 days (SD ± 6.4 days).
Sixteen patients (22.9%) were bitten between dawn and dusk (06:00 
and 18:00), 29 patients (41.4%) were bitten between dusk and dawn 
(18:00 and 06:00) and 25 patients (35.7%) had no records of time of 
bite. Only 26 patients (37.2%) reported within less than four hours after 
being bitten by a snake.  
Forty-three patients (61.4%) sustained snakebites on the lower limb, 
17 patients (24.3%) were bitten on the upper limb, six patients (8.6%) 
were bitten on other parts of the body and four patients (5.7%) had no 
comment on the site of the bite. 
A chart showing the common snakes in Southern Africa was used to 
identify the snakes. Three bites (4.3%) were attributed to puff-adders, 14 
(20.0%) to Mozambique spitting cobras, two (2.9%) to Egyptian cobras 
and two (2.9%) to black mambas. One bite (1.4%) was attributed to the 
southern stiletto snake, six (8.6%) to other species and for 12 patients 
(17.1%), the files indicated that the snakes were never identified. Thirty 
charts (42.8%) had no comment on the snake species (Table I). Thirteen 
out of 70 patients (18.6%) had bite puncture wounds, three (4.3%) had 
therapeutic cut wounds, 32 (45.7%) had swelling and 31 (44.3%) had 
tenderness over the bite marks. One chart indicated that a clinic sister 
had removed a tourniquet before referring the patient to hospital. None 
of the charts indicated usage of either herbal medicine or pressure 
immobilisation bandage. The patients in this study received various 
treatments, as indicated in Table II.
Further analysis showed that the two patients who developed anaphylaxis 
received promethazine prior to polyvalent antivenom administration. Two 
patients (2.9%) received adrenaline and eight patients (11.4%) had 
debridement done. A total of 12 patients developed complications as 
follows: two (2.8%) anaphylaxis, one (1.4%) compartment syndrome and 
nine (12.9%) tissue necrosis. 
Fifty-two patients (74.3%) were discharged, 11 (15.7%) were referred to 
tertiary hospitals and two (2.9%) died from the complications of snake 
envenomation. For the remaining five patients (7.1%), it was not possible 
to determine the outcome from their files; two patients had inadequate 
clinical notes and three patients were admitted but refused hospital 
admission. There was a statistically significant difference between the 
snake species and polyvalent antivenom administration (p = 0.004). 
Only 22 patients (31.4%) received polyvalent antivenom, as shown in 
Table III. There was no consistency among prescribers on the dosages 
of antivenom given, and the most common analgesic administered was 
paracetamol.
Discussion
The study population had a mean age of 27.3 years (SD ± 15.7). 
These findings are quite different from those in other studies. In Nepal, 
snakebites were more common between the ages 11 and 20 years 
(36.7%)11 and in KwaZulu-Natal (KZN), South Africa, 40% of snakebites 
occurred in children under 10 years of age.17 The male preponderance 
Table I: Snakebite and responsible snake species 
Snake species Frequency Percentage
Puff-adders 3 4.3
Mozambique cobras 14 20.0
Egyptian cobras 2 2.9
Black mambas 2 2.9
Southern stiletto snake 1 1.4
Other species 6 8.6
No snake identified 12 17.1
No comment on snake species 30 42.8
Total 70 100.0




Intravenous fluids 31 44.3
Antibiotics 22 31.4
Analgesics 39 55.7
Tetanus toxoid 29 41.4
Elevation of affected limb 20 28.6
Polyvalent antivenin 22 31.4
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in this study is comparable to the findings from Nepal, where snakebites 
were 2.5 times more common in males,10 but different from findings 
from KZN, where the person most at risk of snakebite was the young 
black adult female.18 The difference in gender distribution in this study 
could be explained by the fact that farming is the main occupation in this 
rural area and this tends to attract more males as farmers.
Of the 45 patients for whom there was information on time of bite, about 
two-thirds were bitten between dusk and dawn. This is comparable 
with the Nepal study, where 57% of bites occurred between 16:00 
and midnight,10 and a study from Zimbabwe, where 61% of snakebites 
occurred at night.17 These findings are slightly different from those 
from the KZN study, where only 30% of the bites occurred at night.19 
Forty-three patients (61.4%) sustained bites on the lower limbs and 
these results are comparable with findings from Zimbabwe, where 64% 
of bites were on the lower limb,17 and from KZN, where the victims were 
usually bitten on their bare feet.18 
Only one file indicated that a patient arrived at the local clinic with 
a tourniquet. Although the use of a tourniquet in the management of 
snakebite is discouraged due to the risk of avascular necrosis3,14 and 
possible increase in local envenomation,20 its use is recommended after 
cobra bites since it delays the onset of neurotoxicity, and sudden release 
may lead to precipitous worsening of symptoms.21 Cut wounds around 
the bite site are discouraged since they might increase the risk of sepsis 
and tetanus infection.14
The three groups of snakes of clinical importance (adders, elapids and 
back-fanged snakes) were implicated in about a third of the reported 
snakebites. It was interesting to note that in the group for other species 
and the group where the species were never identified, two patients from 
each group received antivenom and were referred to tertiary hospitals. 
Furthermore, in the group where there was no comment on the snake 
species, five patients received antivenom and two patients developed 
tissue necrosis.
In this study, 42 patients (60%) received promethazine and although 
promethazine is commonly administered, it has been shown not to 
prevent early anaphylactic reactions.22 The two patients who developed 
anaphylactic reactions had received promethazine prior to the antivenom 
administration. Therefore patients should be closely monitored during 
antivenom infusion and the subsequent hours after infusion. The 
use of analgesics, which is an important facet in the management of 
snakebites, was only documented in slightly over half of the patients 
managed (55.5%). 
Hydrocortisone was used in only 32 patients (45.7%), but even though 
hydrocortisone has been shown to delay the appearance of tissue 
necrosis, it does not lessen the severity of the outcome,23 is of no value 
and interferes with the venom/antivenom reaction.24 Intravenous fluids 
were also used in 31 patients (44.3%), and it is recommended that 
colloids be used and, where necessary, plasma or blood be given to 
correct the deficits.25 
Antibiotics were used in a third of the patients but in general, antibiotics 
are usually unnecessary as bacterial infection is uncommon unless 
secondary to necrosis or iatrogenic. Moreover, only 29 patients (41.4%) 
received tetanus toxoid, but since four cases of tetanus have been 
documented following snakebites,15 tetanus toxoid is a recommendation 
for those patients who have not received a booster in the five years 
preceding the snakebite.26 Despite the fact that swelling was documented 
in 32 patients (45.7%), elevation of the affected limb was only prescribed 
for 20 patients (28.6%). 
Only 22 patients (31.4%) received polyvalent antivenom and there 
was a statistically significant difference between the snake species 
and polyvalent antivenom administration (p = 0.004). Due to the risk 
of hypersensitivity reactions,6,25 antivenom is indicated only if serious 
manifestations of envenomation are evident, such as coma, neurotoxicity, 
hypotension, shock, bleeding, disseminated intravascular coagulation 
(DIC) and electrocardiographic (ECG) changes.5,7,8 In the absence of these 
systemic manifestations, swelling involving more than half the affected 
limb, extensive bruising or blistering and progression of the local lesions 
within 30–60 minutes after the bite are other indications.4 Though it was 
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impossible to determine the severity of envenomation in this study, the 
results indicate that the doctors were more likely to administer antivenom 
if the snake was identified as poisonous as opposed to when the snake 
was identified as non-poisonous or not identified at all.                                             
In this study, it was found that two children (2.9%) had died. One was 
bitten by a snake from the adder group and the other by one from the 
elapid group. While there are many factors influencing the outcome 
in victims of snakebites, there is an overall agreement that the case 
fatality rate generally varies from 2% to 10%.5,10,27,28 Mortality is higher 
in children owing to larger amounts of toxin per kilogram body weight 
absorbed.15 
Conclusions
The findings of this study highlighted gaps in the management of 
snakebites at this rural hospital, where they are treated frequently. It 
is crucial for primary care physicians to be familiar with the most 
common venomous snakes in South Africa and the management of their 
bites in humans. Elevation of the affected limb, intravenous fluids and 
administration of analgesia, with close monitoring of patients during and 
after antivenom administration, form the basis of most clinical protocols 
on the management of snakebites. This study further highlighted the 
need for all doctors managing snake envenomation in children to be 
proactive in their management and to refer such patients to centres with 
better support facilities as early as possible.
Study limitations
As this was a retrospective study, some of the information required was 
incomplete. Management of snakebites among health care professionals 
was also not consistent. The dosages of antivenom administered also 
varied, but this was not part of the study objective.
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